CGTX COGNITION THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, COGNITION THERAPEUTICS INC reported revenue of n/a, net income of −$3.93M and diluted EPS of −$0.04; for the fiscal year ended December 2025 revenue was n/a.
CGTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$47.8M, net income −$23.5M (margin n/a), EPS −$0.32
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$54.0M, net income −$34.0M (margin n/a), EPS −$0.86
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$50.7M, net income −$25.8M (margin n/a), EPS −$0.86
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$43.6M, net income −$21.4M (margin n/a), EPS −$0.91
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$28.6M, net income −$11.7M (margin n/a), EPS −$3.13
CGTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$3.93M, EPS −$0.04
- Quarter ended Mar 31, 2026: revenue n/a, net income −$4.57M, EPS −$0.05
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$3.34M, EPS −$0.01
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.93M, EPS −$0.06
- Quarter ended Jun 30, 2025: revenue n/a, net income −$6.73M, EPS −$0.11
- Quarter ended Mar 31, 2025: revenue n/a, net income −$8.48M, EPS −$0.14
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$7.84M, EPS −$0.16
- Quarter ended Sep 30, 2024: revenue n/a, net income −$9.94M, EPS −$0.25
- Quarter ended Jun 30, 2024: revenue n/a, net income −$7.04M, EPS −$0.18
- Quarter ended Mar 31, 2024: revenue n/a, net income −$9.15M, EPS −$0.27
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$8.14M, EPS −$0.27
- Quarter ended Sep 30, 2023: revenue n/a, net income −$6.75M, EPS −$0.22
- Quarter ended Jun 30, 2023: revenue n/a, net income −$4.73M, EPS −$0.16
- Quarter ended Mar 31, 2023: revenue n/a, net income −$6.17M, EPS −$0.21
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$5.18M, EPS −$0.20
- Quarter ended Sep 30, 2022: revenue n/a, net income −$6.63M, EPS −$0.29
- Quarter ended Jun 30, 2022: revenue n/a, net income −$5.75M, EPS −$0.25
- Quarter ended Mar 31, 2022: revenue n/a, net income −$3.84M, EPS −$0.17
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$7.34M, EPS $11.40
- Quarter ended Sep 30, 2021: revenue n/a, net income −$3.11M, EPS −$8.12
CGTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$24.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$28.5M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$16.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$18.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$3.63M, share buybacks n/a
CGTX balance sheet
- Jun 30, 2026: cash $34.0M, total assets $38.9M, total liabilities $5.87M, shareholders' equity $33.0M
- Mar 31, 2026: cash $31.1M, total assets $36.1M, total liabilities $6.23M, shareholders' equity $29.9M
- Dec 31, 2025: cash $36.8M, total assets $48.4M, total liabilities $14.1M, shareholders' equity $34.3M
- Sep 30, 2025: cash $39.3M, total assets $43.4M, total liabilities $6.87M, shareholders' equity $36.5M
- Jun 30, 2025: cash $10.7M, total assets $19.6M, total liabilities $12.6M, shareholders' equity $7.03M
- Mar 31, 2025: cash $16.4M, total assets $23.5M, total liabilities $11.2M, shareholders' equity $12.3M
- Dec 31, 2024: cash $25.0M, total assets $30.2M, total liabilities $11.5M, shareholders' equity $18.8M
- Sep 30, 2024: cash $22.0M, total assets $27.6M, total liabilities $13.1M, shareholders' equity $14.5M
Is CGTX profitable?
No. COGNITION THERAPEUTICS INC lost $16.8M over the last four quarters.
What is CGTX's EPS?
Diluted earnings per share over the last four quarters were −$0.16; −$0.04 in the latest quarter.